Arbutus Biopharma (FRA:I9DN) Cyclically Adjusted FCF per Share: €-0.73 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:I9DN Arbutus Biopharma Corp FRA:I9DN
55 GF Score
Price €3.89
GF Value €41.26
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Arbutus Biopharma Cyclically Adjusted FCF per Share?

Arbutus Biopharma FRA:I9DN +2.10% 55 Cyclically Adjusted FCF per Share is €-0.73 as of Mar. 2026. GuruFocus rates FRA:I9DN with a GF Score™ of 55/100 and a GF Value™ of €41.26 (Possible Value Trap). The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Arbutus Biopharma's adjusted free cash flow per share for the three months ended in Mar. 2026 was €-0.036. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €-0.73 for the trailing ten years ended in Mar. 2026.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 4.40% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was -7.20% per year. During the past 10 years, the average Cyclically Adjusted FCF Growth Rate was -5.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Arbutus Biopharma was 4.40% per year. The lowest was -14.80% per year. And the median was -6.50% per year.

As of today (2026-07-27), Arbutus Biopharma's current stock price is €3.89. Arbutus Biopharma's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was €-0.73. Arbutus Biopharma's Cyclically Adjusted Price-to-FCF of today is .


Arbutus Biopharma  (FRA:I9DN) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Arbutus Biopharma Cyclically Adjusted FCF per Share Related Terms


Arbutus Biopharma Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Arbutus Biopharma's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Arbutus Biopharma Cyclically Adjusted FCF per Share Chart

Arbutus Biopharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.61 -0.95 -0.96 -0.97 -0.74

Arbutus Biopharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.87 -0.82 -0.79 -0.74 -0.73

FRA:I9DN vs TBPH, ANNX, SANA: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, Arbutus Biopharma's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Arbutus Biopharma Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arbutus Biopharma's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Arbutus Biopharma's Cyclically Adjusted Price-to-FCF falls into.


FRA:I9DN
55GF Score
Arbutus Biopharma Corp FRA:I9DN
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Arbutus Biopharma Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Arbutus Biopharma's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.036/330.2130*330.2130
=-0.036

Current CPI (Mar. 2026) = 330.2130.

Arbutus Biopharma Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 -0.300 241.018 -0.411
201609 -0.247 241.428 -0.338
201612 -0.303 241.432 -0.414
201703 -0.361 243.801 -0.489
201706 -0.134 244.955 -0.181
201709 -0.248 246.819 -0.332
201712 -0.162 246.524 -0.217
201803 -0.298 249.554 -0.394
201806 -0.273 251.989 -0.358
201809 -0.208 252.439 -0.272
201812 -0.274 251.233 -0.360
201903 -0.264 254.202 -0.343
201906 -0.278 256.143 -0.358
201909 -0.379 256.759 -0.487
201912 -0.205 256.974 -0.263
202003 -0.207 258.115 -0.265
202006 -0.112 257.797 -0.143
202009 -0.130 260.280 -0.165
202012 -0.143 260.474 -0.181
202103 -0.162 264.877 -0.202
202106 -0.125 271.696 -0.152
202109 -0.135 274.310 -0.163
202112 -0.130 278.802 -0.154
202203 0.126 287.504 0.145
202206 -0.130 296.311 -0.145
202209 -0.126 296.808 -0.140
202212 -0.104 296.797 -0.116
202303 -0.158 301.836 -0.173
202306 -0.113 305.109 -0.122
202309 -0.122 307.789 -0.131
202312 -0.094 306.746 -0.101
202403 -0.102 312.332 -0.108
202406 -0.072 314.175 -0.076
202409 -0.099 315.301 -0.104
202412 -0.052 315.605 -0.054
202503 -0.065 319.799 -0.067
202506 -0.071 322.561 -0.073
202509 -0.026 324.800 -0.026
202512 -0.021 324.054 -0.021
202603 -0.036 330.213 -0.036

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of €-0.73 mean?
Arbutus Biopharma (FRA:I9DN) has a Cyclically Adjusted FCF per Share of €-0.73 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Arbutus Biopharma and its competitors.
Is Arbutus Biopharma's Cyclically Adjusted FCF per Share too high?
Arbutus Biopharma's current Cyclically Adjusted FCF per Share is €-0.73. Overall, Arbutus Biopharma has a GF Score™ of 55/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Arbutus Biopharma's Cyclically Adjusted FCF per Share compare to TBPH and ANNX?
Arbutus Biopharma's Cyclically Adjusted FCF per Share of €-0.73 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Arbutus Biopharma and its competitors. Arbutus Biopharma's current Cyclically Adjusted FCF per Share is €-0.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arbutus Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Arbutus Biopharma (FRA:I9DN) is currently considered Possible Value Trap. The stock's GF Value™ is €41.26, compared to a current price of €3.89 — trading 90.6% below its estimated fair value. The current Cyclically Adjusted FCF per Share is €-0.73. Arbutus Biopharma's overall GF Score™ is 55/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Arbutus Biopharma (FRA:I9DN), the current Cyclically Adjusted FCF per Share is €-0.73 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Arbutus Biopharma (FRA:I9DN) Overvalued in 2026?

Based on GuruFocus' analysis, Arbutus Biopharma stock appears to be undervalued. The current stock price of €3.89 is trading 90.6% below its estimated GF Value™ of €41.26. GuruFocus considers Arbutus Biopharma to be Possible Value Trap.

Key valuation signals for FRA:I9DN:

  • Cyclically Adjusted FCF per Share: €-0.73
  • GF Value™: €41.26 vs. price of €3.89 (90.6% below fair value)
  • GF Score™: 55/100 with 5 warning signs

No single metric tells the full story. See the FRA:I9DN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Arbutus Biopharma Business Description

Other Exchanges ABUS:USAI9DN:Germany
Address 701 Veterans Circle, Warminster, PA, USA, 18974
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.
55GF Score

Get the complete analysis for FRA:I9DN

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.89
Price
€41.26
GF Value